Clinical trials: High-risk Locally Advanced
Non Small Cell Lung Cancer
Atezolizumab Plus Bevacizumab in First Line NSCLC Patients
This is a multi-center phase II clinical trial of atezolizumab in combination with bevacizumab as first line treatment for locally advanced or metastasic high-intermediate tumour mutation burden selected NSCLC patients.
- Trial name
- TELMA (NCT03836066)
- Testing
- Atezolizumab-Bevacizumab
- Where
- 25 sites in Spain
- Volunteers
- 41 people
- Sponsor
- Fundación GECP
Esophageal Squamous Cell Carcinoma
Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence
In this study, participants with histologically diagnosed locally advanced esophageal squamous cell carcinoma who have received preoperative cisplatin-based chemoradiotherapy followed by surgery harbouring high risk of tumor…
- Trial name
- NCT03322267
- Testing
- Pembrolizumab
- Where
- Taiwan
- Volunteers
- 26 people
- Sponsor
- National Taiwan University Hospital
Carcinoma, Squamous Cell
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
This is a randomized, double-blind, study that compares pembrolizumab (MK-3475) with placebo given as adjuvant therapy in participants with high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) that have…
- Trial name
- NCT03833167
- Testing
- Pembrolizumab
- Where
- 181 sites in United States, Argentina and 22 more
- Volunteers
- 450 people
- Sponsor
- Merck Sharp & Dohme LLC
Sarcoma
Trial of Cetuximab in Patients With Metastatic and/or Locally Advanced Soft Tissue and Bony Sarcomas
The purpose of this study is to explore how this cancer is affected by a new medication, cetuximab. Cetuximab is directed towards a protein called EGFR (epidermal growth factor receptor), that is found in some types of cancer.
- Trial name
- NCT00148109
- Testing
- Cetuximab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Michigan Rogel Cancer Center
Recurrent Melanoma, Stage IIIA Skin Melanoma
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
This randomized phase III trial studies aldesleukin with vaccine therapy to see how well it works compared to aldesleukin alone in treating patients with melanoma that has spread from where it started to nearby tissue or lymph…
- Conditions
- Recurrent Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma
- Trial name
- NCT00019682
- Testing
- Aldesleukin, gp100 Antigen, Montanide ISA 51 VG
- Where
- 19 sites in United States
- Volunteers
- 185 people
- Sponsor
- National Cancer Institute (NCI)
Basal Cell Carcinoma
Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes
The purpose of this study is to investigate the safety and effectiveness of oral vismodegib therapy in the treatment of different 'histologic subtypes' of basal cell skin cancer (BCC).
- Trial name
- NCT01700049
- Testing
- vismodegib (150 mg PO daily)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Mayo Clinic
Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer
High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
This randomized phase II trial studies how well high or standard intensity radiochemotherapy after gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel) work compared with…
- Trial name
- NCT01921751
- Testing
- low intensity radiation therapy, Capecitabine, Gemcitabine
- Where
- 46 sites in United States
- Volunteers
- 20 people
- Sponsor
- Radiation Therapy Oncology Group
Head and Neck Cancer
Stereotactic Radiosurgery in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer
RATIONALE: Stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This phase I trial is studying the side effects of stereotactic radiosurgery in treating…
- Trial name
- NCT00851253
- Testing
- stereotactic radiosurgery
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Boston Medical Center
Invasive Breast Cancer
Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer
This is a single-arm, open-label, phase 2 study that will enroll 36 subjects, who have pathologically proven diagnosis of invasive breast cancer, clinical stage tumor 1-3 (cT1-T3), node 0-3 (cN0-N3), metastasis 0 (cM0), hormone…
- Trial name
- CemiHALT (NCT04243616)
- Testing
- Cemiplimab, Paclitaxel, Carboplatin (not mandatory)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Medical College of Wisconsin
Rectal Cancer
Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer
The purpose of this study is to evaluate the use of chemotherapy, radiation therapy and bevacizumab before surgery in patients with locally advanced rectal cancer (LARC).
- Trial name
- BRANCH (NCT01481545)
- Testing
- Radiation therapy, Oxaliplatin, Raltitrexed
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute, Naples
Lung Cancer Stage II, Lung Cancer Stage III
Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC
This is a single-arm, single-stage Phase II study designed to evaluate the 1-year PFS rate in subjects with locally-advanced NSCLC (stage II/III) and treated with Stereotactic Body Radiation Therapy (SBRT) followed by concurrent…
- Conditions
- Lung Cancer Stage II, Lung Cancer Stage III, Non Small Cell Lung Cancer
- Trial name
- NCT03141359
- Testing
- SBRT, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Wake Forest University Health Sciences
Prostate Cancer
Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer
This randomized study is looking at the benefits of using docetaxel (chemotherapy) added to one of the standard treatments (radiation and hormones) for men with high-risk prostate cancer.
- Trial name
- NCT00116142
- Testing
- Docetaxel, Androgen Hormonal Suppression and Radiation, Androgen Suppression Therapy and Radiation Therapy
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- Dana-Farber Cancer Institute
Carcinoma, Squamous Cell of Head and Neck, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck
This research study is evaluating a drug called buparlisib (BKM120) as a possible treatment for locally advanced head and neck squamous cell cancer.
- Conditions
- Carcinoma, Squamous Cell of Head and Neck, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Hypopharyngeal Cancer, Early Invasive Cervical Squamous Cell Carcinoma
- Trial name
- NCT02113878
- Testing
- BKM120, Cisplatin, Intensity-modulated radiotherapy (IMRT)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Dana-Farber Cancer Institute
Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
This randomized phase III trial studies octreotide acetate and recombinant interferon alfa-2b to see how well it works compared to octreotide acetate and bevacizumab in treating patients with high-risk neuroendocrine tumors that…
- Conditions
- Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm, Neuroendocrine Tumor
- Trial name
- NCT00569127
- Testing
- Bevacizumab, Laboratory Biomarker Analysis, Octreotide Acetate
- Where
- 493 sites in United States
- Volunteers
- 427 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00096226
- Testing
- Induction Carboplatin, Induction Paclitaxel, Resection
- Where
- 22 sites in United States
- Volunteers
- 60 people
- Sponsor
- Radiation Therapy Oncology Group
Rectal Cancer
Study of High-Dose-Rate Endorectal Brachytherapy (HDRBT) in the Treatment of Locally Advanced Low Rectal Cancer
This research is being done to see how effective high-dose rate endorectal brachytherapy (HDRBT) is in treating cancer of the lowest part of the bowel (rectum).
- Trial name
- HDRBT (NCT01226979)
- Testing
- High-dose endorectal brachytherapy (HDRBT)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Head and Neck Squamous Cell Carcinoma
Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer
The goal of this research study is to learn which therapy order (adding pembrolizumab during vs. after cisplatin and radiation) may be more effective in treating head and neck cancer, as well as learn the side effects of these…
- Trial name
- NCT02777385
- Testing
- Pembrolizumab, Cisplatin, IMRT
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Dan Zandberg
Cancer
Chemoradiation +Gemcitabine +Continuous 5-FU (Fluorouracil) Followed by High Dose Brachytherapy/Stereotactic Radiation Boost in Locally Advanced Intra/Extrahepatic Cholangiocarcinoma
OBJECTIVES: This study proposes to evaluate the feasibility of delivery of this treatment in terms of toxicity. If toxicity is not acceptable, the treatment is not feasible.
- Trial name
- NCT00983541
- Testing
- Fluorouracil (5-FU), Brachytherapy or SBRT (Stereotactic body radiation therapy), Gemcitabine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Utah
Metastatic Melanoma, Locally Advanced Refractory/Recurrent Melanoma
Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors
To determine whether special tumor fighting cells that is taken from participants' tumors and grown in the laboratory and then given back to the participant will fight the participant's cancer when their immune system is…
- Conditions
- Metastatic Melanoma, Locally Advanced Refractory/Recurrent Melanoma, Metastatic Head and Neck Cancer, Locally Advanced Refractory/Recurrent Head and Neck Cancer
- Trial name
- NCT03991741
- Testing
- Autologous Tumor Infiltrating Lymphocytes, High-Dose Interleukin 2
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Gregory Daniels
Sarcoma, Soft Tissue Sarcoma
Gemcitabine Plus Ascorbate for Sarcoma in Adults
This study will enroll patients who have a diagnosis of locally advanced, unresectable or metastatic soft tissue or bone sarcoma (except gastrointestinal stromal tumors and Kaposi's sarcoma) from any site.
- Conditions
- Sarcoma, Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma, Metastatic Bone Tumor
- Trial name
- NCT03468075
- Testing
- Ascorbate, Gemcitabine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Mohammed Milhem, MBBS